Trial Profile
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs AZD-8186 (Primary) ; Docetaxel (Primary)
- Indications Advanced breast cancer; Carcinoma; HER2 negative breast cancer; Prostate cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- 26 Sep 2023 Planned End Date changed from 27 Mar 2024 to 22 Sep 2024.
- 29 Mar 2023 Planned End Date changed from 1 Apr 2023 to 27 Mar 2024.
- 02 Apr 2022 Planned End Date changed from 1 Apr 2022 to 1 Apr 2023.